FDA approves Johnson & Johnson's IMAAVY (nipocalimab-aahu) to treat warm autoimmune haemolytic anaemia

Antengene's Phase I study of ATG-201 in B cell-related autoimmune diseases approved in Australia

Alfasigma to acquire Nordic Pharma, expanding specialty care portfolio

European Commission approves RINVOQ for severe alopecia areata

AbCellera and Vertex agree collaboration to develop multispecific T-cell engagers

AbelZeta's C-CAR168 registrational Phase II trial in refractory Lupus Nephritis granted FDA clearance

argenx agrees to acquire Forte Biosciences for USD2.2bn to add anti-CD122 antibody FB102

AbelZeta's C-CAR168 receives EMA PRIME designation for Lupus Nephritis and Systemic Lupus Erythematosus

Sareum completes dosing in Phase 2-enabling toxicology programme for SDC-1801

FDA grants priority review to Genentech's Gazyva for primary membranous nephropathy

Lynk Pharmaceuticals completes patient enrolment for zemprocitinib Phase III clinical trial in ankylosing spondylitis

Newbury Pharmaceuticals receives Swedish approval for generic tofacitinib

Antengene receives USD60m upfront payment from UCB

Teva and Polpharma Biologics enter global licensing agreement for biosimilar candidate to Ocrevus

United Therapeutics acquires Thymmune Therapeutics to expand regenerative cell therapy pipeline